Skip to main content

Table 2 Risk of SPC after BC diagnosis by follow-up, age, and period (1993–2013)

From: Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

  Total latency (months) Age (years) Period
  < 12 12–59 60–119 ≥120 0–39 40–59 ≥ 60 1993–2000 2001–2013
  SIR O/E CI SIR SIR SIR SIR SIR SIR SIR SIR SIR
All SPCs 0.94# (3821/4086.59) (0.91–0.97) 1.21# 0.89# 0.92# 0.86# 1.50# 1.04 0.90# 0.85# 0.99
All SPCs excluding BC, KC, pelvic and ureteral cancer 0.96# (3751/3921.87) (0.93–0.99) 1.20# 0.91# 0.95 0.90# 1.36 1.06 0.92# 0.87# 1.01
Buccal cavity, pharynx 0.79 (53/67.09) (0.59–1.03) 0.23# 1.09 0.62 0.76 0 1.03 0.71# 0.68 0.87
Tongue 0.37# (4/10.95) (0.10–0.94) 0 0.43 0.32 0.57 0 0.67 0.26# 0.22 0.47
Salivary gland 0.92 (6/6.51) (0.34–2.01) 0 1.10 1.58 0 0 1.17 0.85 0.76 1.03
Tonsil 0.27# (2/7.32) (0.03–0.99) 0 0.66 0 0 0 0.40 0.21 0 0.44
Hypopharynx 1.19 (19/15.94) (0.72–1.86) 0.49 1.33 0.86 2.01 0 1.69 1.05 1.48 0.98
Digestive system 0.85# (1833/2160.13) (0.81–0.89) 0.81# 0.79# 0.96 0.82# 1.41 0.95 0.81# 0.79# 0.89#
Esophagus 0.97 (94/97.04) (0.78–1.19) 0.96 0.96 1.07 0.80 0 1.05 0.95 0.83 1.08
Stomach 0.79# (632/796.08) (0.73–0.86) 0.73# 0.73# 0.87# 0.87 1.47 0.92 0.75# 0.73# 0.84#
Small intestine 1.43 (20/14.02) (0.87–2.20) 2.31 1.55 1.22 0.84 0 1.33 1.47 2.13# 0.95
Colon 0.84# (271/321.74) (0.74–0.95) 0.95 0.87 0.86 0.70# 1.72 0.90 0.82# 0.77# 0.88
Rectum, rectosigmoid junction 0.91 (233/255.77) (0.80–1.04) 1.15 0.75# 1.02 0.95 1.59 0.88 0.91 0.82 0.96
Anus, anal canal 0.97 (5/5.15) (0.32–2.27) 1.51 0.46 1.34 1.20 0 2.12 0.72 0.89 1.03
Liver 0.79# (240/304.17) (0.69–0.90) 0.63# 0.74# 0.94 0.79 1.09 0.95 0.71# 0.77# 0.80#
Gallbladder 0.77 (43/55.52) (0.56–1.04) 1.18 0.57# 0.86 0.83 0 0.92 0.75 0.71 0.82
Bile ducts, other biliary 0.92 (166/180.66) (0.78–1.07) 0.55# 0.92 1.18 0.73 2.04 0.95 0.91 0.92 0.92
Pancreas 0.98 (122/124.96) (0.81–1.17) 0.67 0.98 1.19 0.82 2.2 1.27 0.90 0.81 1.08
Respiratory system 1.05 (848/807.86) (0.98–1.12) 1.06 1.07 1.01 1.05 0 1.27# 1.01 0.93 1.13#
Nose, nasal cavity, ear 1.07 (8/7.51) (0.46–2.10) 2.06 1.57 0.46 0 0 0 1.41 0.62 1.39
Larynx 1.20 (58/48.45) (0.91–1.55) 2.18# 1.09 0.87 1.26 0 1.18 1.21 1.1 1.27
Lung, bronchus 1.05 (782/748.26) (0.97–1.12) 0.98 1.07 1.03 1.06 0 1.30# 1 0.93 1.13#
Female breast 1.12 (34/30.38) (0.78–1.56) 1.35 0.72 1.11 1.91 0.90 1.19 1.09 1.70# 0.78
Female genital system 1.10 (33/29.98) (0.76–1.55) 1.71 1.16 0.59 1.33 2.75 0.97 1.07 1.27 0.96
Male genital system 1.45# (513/353.32) (1.33–1.58) 4.04# 1.30# 1.04 0.95 5.18 1.66# 1.41# 1.30# 1.53#
Prostate 1.46# (505/346.97) (1.33–1.59) 4.08# 1.31# 1.03 0.95 7.54 1.66# 1.41# 1.32# 1.53#
Testis 3.95 (3/0.76) (0.82–11.55) 0 6.05 4.61 0 0 4.17 4.76 0 6.83#
Urinary system 0.73# (170/232.70) (0.62–0.85) 2.03# 0.72# 0.42# 0.37# 6.63# 0.89 0.65# 0.61# 0.81#
Urinary bladder 0.45# (63/139.70) (0.35–0.58) 1.63# 0.49# 0.12# 0.08# 12.41# 0.46# 0.41# 0.33# 0.54#
Kidney parenchyma 1.47# (100/67.98) (1.20–1.79) 3.23# 1.44# 1.04 1.08 4.54# 1.40 1.44# 1.32 1.56#
Renal pelvis, other urinary 0.28# (7/25.02) (0.11–0.58) 1.03 0.10# 0.40 0.00# 0 0.90 0.15# 0.43 0.19#
Brain, central nervous system 0.76 (16/21.09) (0.43–1.23) 0.38 0.91 0.97 0.28 0 0.56 0.85 0.72 0.79
Thyroid 1.21 (107/88.29) (0.99–1.46) 2.24# 1.29 0.97 0.83 1.08 1.35# 1.09 1.04 1.28#
Lymphatic, hematopoietic 0.75# (98/130.52) (0.61–0.92) 1.08 0.64# 0.73 0.83 0.63 0.57# 0.81 0.69# 0.79
Hodgkin lymphoma 0.77 (2/2.58) (0.09–2.80) 3.11 0.92 0 0 0 0 1.15 0.99 0.64
Non-Hodgkin lymphoma 0.69# (47/68.39) (0.50–0.91) 1.21 0.75 0.35# 0.75 1.17 0.43# 0.76 0.64 0.71
Myeloma 0.82 (19/23.27) (0.49–1.28) 1.09 0.64 0.87 0.95 0 0.79 0.83 0.70 0.89
Leukemia 0.82 (32/38.93) (0.56–1.16) 0.84 0.44# 1.31 0.90 0 0.68 0.88 0.78 0.85
  1. SIR: standardized incidence ratio, CI: confidence interval, BC: bladder cancer, SPC: second primary cancer, KC: kidney cancer, O/E: Observed/Expected,
  2. # significant at alpha = 0.05